OmniLytics Completes Financing Round

Subordinated debt round to fund expansion.

Salt Lake City — (July 21, 2006) OmniLytics, Inc., a biotech company focused on developing safe, natural, effective solutions for infectious disease and pest control, today announced the completion of a subordinated debt financing round and the expansion of operations in Salt Lake City, Utah. The financing was led by B.C. Select Fund, LLC and N.S. Japan Fund, Series 1.

The Company will use the proceeds of the financing to increase production capacity for the AgriPhage™ (a natural bacteriocide used by commercial vegetable growers) product line, to expand development in the Food & Water Safety, Industrial and Dietary Supplement markets, and to extend sales into Mexico and Canada.

Jeff Collett, managing director of BC Select Fund states, "OmniLytics recently received its first registration with the EPA for its AgriPhage product line, making it the first company to ever receive a regulatory approval for the use of a bacteriophage product in the United States. We believe that that registration continues to validate not only the reality of bacteriophage products being able to overcome the huge regulatory hurdles in the United States and other international markets, but also confirms the company’s first-to-market position." Mr. Collett continues, “We continue to invest in OmniLytics and its management team, due to the sound technology and vast potential for adoption into the targeted market segments.”

"Since receiving our EPA registration last December the demand for our market-leading AgriPhage product has surged. This demand, coupled with advancements in our manufacturing processes, has mandated additional capital investments in both equipment and manpower." states Justin Reber, CEO & President of OmniLytics, "Additionally, both domestic and international demand continues to increase as commercial growers look to eliminate the use of harsh chemicals and antibiotics in favor of effective organic solutions."

OmniLytics is already the largest producer of phage-based therapy products in the world, delivering thousands of gallons of product every month. This production volume advantage has allowed OmniLytics to develop technology and processes to improve the concentration and efficacy of
naturally-occurring phage for commercial applications.

About OmniLytics, Inc.

OmniLytics is a biotech company focused on developing safe, natural, effective solutions for infectious disease and pest control. OmniLytics is located in SLC, Utah. OmniLytics is pioneering research and development of bacteriophage solutions for control of microorganisms in agricultural, food & water, industrial, pharmaceutical, and defense markets. OmniLytics’ proprietary formulas and processes optimize the use of natural bacteriophage for commercial applications. For more information about OmniLytics, visit www.omnilytics.com.

Contacts:

Press or Product

Tony Swensen
OmniLytics, Inc.
801.746.3600 x304
tswensen@omnilytics.com

Business or Investments

Alan Walbeck
OmniLytics, Inc.
801.746.3600 x320
awalbeck@omnilytics.com

Contact the OmniLytics PR Department Here.